Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baijun Fang

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
The Oncologist|August 29, 2019
1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in ChinaXiaozhe Li, Wenming Chen, Yin Wu, et al.
Frontiers in Oncology|September 20, 2021
Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective StudyNing Li, Wenying Deng, Guifang Zhang, et al.
Bone Marrow Transplantation|December 7, 2018
Treatment of Epstein-Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocyte infusionJuanjuan Zhao, Yingling Zu, Lijie Han, et al.
Cancer Medicine|July 20, 2024
Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myelomaWenjiao Tang, Yan Li, Li Zhang, et al.
Journal for Immunotherapy of Cancer|August 15, 2020
Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virusLu Han, Jian Zhou, Keshu Zhou, et al.
American Journal of Hematology|January 22, 2025
CM313 Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter, Phase 1 Dose-Escalation and Dose-Expansion TrialHuixing Zhou, Zhongxia Huang, Baijun Fang, et al.
Scientific Reports|January 9, 2021
Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAAYingling Zu, Jian Zhou, Yuewen Fu, et al.
Leukemia Research|March 27, 2007
Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinibBaijun Fang, Yongping Song, Zhengtao Han, et al.
Frontiers in Oncology|June 18, 2025
Cord blood therapy for pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: case series and reviewZhen Li, Sujing Zhuang, Ruirui Gui, et al.
Frontiers in Oncology|May 31, 2023
A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapyZhenghua Huang, Zhen Li, Juan Wang, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
The Oncologist|August 29, 2019
1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in ChinaXiaozhe Li, Wenming Chen, Yin Wu, et al.
Frontiers in Oncology|September 20, 2021
Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective StudyNing Li, Wenying Deng, Guifang Zhang, et al.
Bone Marrow Transplantation|December 7, 2018
Treatment of Epstein-Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocyte infusionJuanjuan Zhao, Yingling Zu, Lijie Han, et al.
Cancer Medicine|July 20, 2024
Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myelomaWenjiao Tang, Yan Li, Li Zhang, et al.
Journal for Immunotherapy of Cancer|August 15, 2020
Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virusLu Han, Jian Zhou, Keshu Zhou, et al.
American Journal of Hematology|January 22, 2025
CM313 Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter, Phase 1 Dose-Escalation and Dose-Expansion TrialHuixing Zhou, Zhongxia Huang, Baijun Fang, et al.
Scientific Reports|January 9, 2021
Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAAYingling Zu, Jian Zhou, Yuewen Fu, et al.
Leukemia Research|March 27, 2007
Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinibBaijun Fang, Yongping Song, Zhengtao Han, et al.
Frontiers in Oncology|June 18, 2025
Cord blood therapy for pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: case series and reviewZhen Li, Sujing Zhuang, Ruirui Gui, et al.
Frontiers in Oncology|May 31, 2023
A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapyZhenghua Huang, Zhen Li, Juan Wang, et al.
Pageof 9